CVS Pulled the Plug on Zepbound?!

In this episode of the Dr. Lift podcast, hosts Dr. Spencer Nadolsky and Dr. Karl discuss the recent changes in obesity medication coverage, particularly focusing on the CVS Caremark decision to drop ZEPBound from their formulary in favor of Wegovi. They explore the implications of this decision for patients and providers, the role of pharmacy benefit managers (PBMs) in healthcare, and the ongoing advocacy efforts to ensure access to effective obesity treatments. The conversation highlights the complexities of insurance coverage, the need for patient-centered care, and the importance of making medications more affordable. - The recent changes in obesity medication coverage have raised concerns among providers and patients. - CVS Caremark's decision to drop ZEPBound has sparked a petition advocating for better access to medications. - Pharmacy Benefit Managers (PBMs) play a significant role in determining medication coverage and costs. - There is a need for more nuanced insurance policies that consider patient needs and clinical severity. - Advocacy efforts are crucial in reversing negative trends in medication coverage. - Patients often face challenges with prior authorization processes when switching medications. - The cost of obesity medications is a significant barrier to access for many patients. - Insurance companies are increasingly dropping coverage for anti-obesity medications, impacting patient care. - The conversation emphasizes the importance of patient-centered care in obesity treatment. - There is a call for making obesity medications more affordable and accessible to patients. https://www.change.org/p/stop-cvs-caremark-s-zepbound-ban-restore-coverage-of-the-superior-obesity-medication Click to join Dr. Spencer's online clinic if you need help with this